Pam Randhawa


Pam Randhawa, CEO and Founder of Empiriko, has 25 years of leadership experience in the healthcare/life science industries with expertise ranging from policy, corporate strategy, product development, and advanced analytics for Fortune 500 companies, startups, and government. Prior to founding Empiriko, she co-founded AgroGreen Biofuels, an alternative biofuels technology company. Previously, Pam held several executive positions with major healthcare technology companies.

Pam currently serves on the Board of Directors (past Chair) of the Massachusetts Biotechnology Council and on the Board of Directors of the Massachusetts Life Sciences Center (MLSC), a state investment agency responsible for $1.6 billion fund to support life sciences innovation. She also serves on the Board of Directors of Hercules Capital with $4.2 billion assets under management.

Pam has previously served in leadership roles on several boards/councils focused on strategic initiatives promoting scientific innovation as a vehicle for the public good. These include the World Economic Forum’s Global Future Council on Biotechnology; as Chair of the NSF/NIJ Industrial Advisory Board of Center for Advanced Research in Forensic Science; and the NIH review panel for SBIR/STTR Commercialization Readiness Pilot Program.

Pam has a strong interest in reinvesting in the community and mentoring the next generation of thought leaders as a previous member of the Commonwealth of Massachusetts Economic Development Planning Council, the Women’s Workforce Council, and as a judge for the Harvard Business School’s New Venture Competition.

Pam holds a B.A. in economics from the University of Rajasthan, India, and an MPM from the Heinz School of Public Policy & Management at Carnegie-Mellon University. She developed her passion for analytics as a member of the MIT blackjack card counting team featured in the movie “21”.

Oliver Dick

Oliver brings 30+ years of experience in the life sciences industry, has worked in pharma, biotechnology and in vitro diagnostics. His areas of expertise fall under Supply Chain Management, Planning, Production, QC, QA, Engineering, Technology Transfer and Process Improvement. Amongst his vast experience, Oliver held functions such as Vice President of Global Manufacturing at QIAGEN, Chief Operating Officer at Miltenyi Biotec or Chief Operating Office of Resolve Biosciences. He demonstrated exceptional leadership and expertise in driving manufacturing excellence on a global scale.

Oliver has a proven ability to streamline processes, optimize production efficiency, and foster a culture of innovation. He was responsible for strategy development, scaling, cost control and quality and was part of multiple M&A projects and transfer of many new products from acquisition or own development. Today Oliver offers his expertise mainly through his own Consultancy Service Company ODICON.


Christoph Brandenberger is a Managing Director at BGL and a leader in the firm’s Diagnostics, Research Tools & Medical Devices investment banking group. He has more than 20 years of experience in all aspects of mergers and acquisitions, commercialization and partnering agreements, and private placements.

A native of Austria and fluent in German, Christoph’s investment banking experience, coupled with his background in international business, has made him a sought-after advisor in both the domestic and international healthcare markets.

Prior to joining BGL, Christoph served as managing director for Healthios Capital Markets, LLC. Christoph started his career as a financial analyst for Bank of America Securities.


John Riddle

John Riddle is a Managing Director and member of the BGL Executive Committee. He has more than 30 years of investment banking and capital markets experience, advising clients across a broad spectrum of mergers and acquisitions, capital markets activities, and strategic assignments.

John leads BGL’s advisory activities in the Healthcare & Life Sciences investment banking group, which comprises both corporate investment banking and real estate capital markets capabilities. Together with his team, John maintains an ongoing coverage effort with broad activity across several sectors, including health facilities, physician services, and ancillary providers; diagnostics and research tools; medical device and products; and select healthcare technology verticals, including payor services, data analytics, and clinical automation.


Dr. Mirko Stange

Born in Bremen, Germany in 1974, Dr. Mirko Stange is a diagnostics and life sciences expert with a proven track record in turning around and commercializing innovations. He possesses extensive executive management experience, having led diagnostics and biotech startups, as well as developing and conducting consulting products. Following the completion of his Ph.D. in Biochemistry and Biophysics at the University of North Carolina at Chapel Hill, Dr. Stange began his career in 2004 at the strategy consultancy McKinsey. Subsequently, he worked with the turnaround-specialized advisory firm Droege & Comp., primarily serving clients from the pharma and chemistry industry in Germany and Switzerland.

In 2008, he founded an independent Life Sciences consultancy in Germany where, to date, he leads and directs a team of international experts. This team identifies and funds SMEs with high potential for national and international leverage. In addition to his over ten years of experience in independent corporate finance and management consulting, Mirko Stange provides interim management services to selected clients. To date, three companies co-founded and managed/advised by Dr. Stange have been successfully exited. Leveraging his scientific background, he is also a named inventor on several granted and pending patents.


FName LName

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.